1. IARC. Some Pharmaceutical Drugs, IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans, vol. 66. International Agency for Research on Cancer, Lyon, 1996.
2. Hard GC, Iatropoulos MJ, Jordan K, Radi L Kaltenberg OP, Imondi AR, Williams GM. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 1993; 53:4534–4541.
3. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993; 53:3919–3924.
4. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993; 14:315–317.
5. Hirsimaki P, Hirsimaki Y, Nieminen L, Payne BJ. Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch Toxicol 1993; 67:49–54.